search
Back to results

Auditory Neural Function in Implanted Patients With Usher Syndrome

Primary Purpose

Usher Syndrome, Cochlear Implantation

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Experimental manipulation of stimulation parameters
Sponsored by
Ohio State University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Usher Syndrome focused on measuring Auditory Electrophysiology

Eligibility Criteria

1 Year - 85 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Minimum of 6 months of listening experience with cochlear implant
  • Diagnosed with Usher syndrome or idiopathic hearing loss

Exclusion Criteria:

  • Severe medical comorbidities
  • Electrode malposition or migration as determined based on imaging results

Sites / Locations

  • Boston children's Hospital
  • Gina Hounam
  • The Ohio State UniversityRecruiting
  • Vanderbilt University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Usher Syndrome

Idiopathic Hearing Loss

Arm Description

Adult and pediatric cochlear implant users with Usher syndrome

Adult and pediatric cochlear implant users with idiopathic hearing loss

Outcomes

Primary Outcome Measures

The electrically evoked compound action potential
The primary outcome measure is the neural response generated by the electrically-stimulated cochlear nerve, which can be considered a health-related, biomedical outcome.

Secondary Outcome Measures

Full Information

First Posted
May 24, 2021
Last Updated
April 3, 2023
Sponsor
Ohio State University
Collaborators
National Institute on Deafness and Other Communication Disorders (NIDCD)
search

1. Study Identification

Unique Protocol Identification Number
NCT04906135
Brief Title
Auditory Neural Function in Implanted Patients With Usher Syndrome
Official Title
Auditory Neural Function in Implanted Patients With Usher Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 1, 2021 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ohio State University
Collaborators
National Institute on Deafness and Other Communication Disorders (NIDCD)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Usher syndrome (USH) causes extensive degeneration in the cochlear nerve (CN), especially in CN fibers innervating the base of the cochlea. As the first step toward developing evidence-based practice for managing implant patients with USH, this study evaluates local neural health, as well as the neural encoding of temporal and spectral cues at the CN in implanted patients with USH. Aim 1 will determine local CN health in patients with USH by assessing the sensitivity of the electrically evoked compound action potential to changes in interphase gap and pulse polarity. Aim 2 will determine group differences in neural encoding of temporal and spectral cues at the CN between patients with USH and patients with idiopathic hearing loss. Aim 3 will use supervised machine learning techniques to develop an objective tool for assessing the electrode-neuron interface at individual electrode locations.
Detailed Description
Usher syndrome (USH) is an autosomal recessive disorder characterized by hearing loss, visual impairment, and in some cases, vestibular dysfunction. It is the leading cause of hereditary deaf-blindness in humans. USH causes extensive degeneration in the cochlear nerve (CN), especially in CN fibers innervating the base of the cochlea. Whereas there is no treatment for arresting this degenerative process or for restoring visual loss, the restoration of auditory input is possible with cochlear implantation. Due to the progressive deterioration in vision, using visual cues for communication will eventually become impossible. Therefore, the importance of optimizing auditory inputs through cochlear implants (CIs) for patients with USH is paramount. However, patients with USH have much higher rates of neurological, mental, or behavioral disorders than the general CI patient population, which limits their ability to provide reliable behavioral responses or sufficient verbal descriptions of their auditory perception, especially for pediatric patients. In addition, optimal programming parameters for CI users with CN damage differ from those used in typical CI users due to declined CN responsiveness to electrical stimulation. As a result, the clinical programming process in implanted patients with USH can be extremely challenging. To date, auditory neural encoding of electrical stimulation in patients with USH has not been systematically evaluated. Consequently, the field lacks evidence-based practice guidelines for managing implanted patients with USH. For patients who cannot provide reliable feedback, clinicians rely on a "trial-and-error" approach for adjusting CI programming settings, which ultimately may not result in appropriate programming maps for individual patients. Therefore, there is an urgent need to develop objective clinical tools for optimizing CI settings for these patients. As the first step toward developing evidence-based practice for managing patients with USH, this study evaluates local neural health, as well as the neural encoding of temporal and spectral cues at the CN in implanted patients with USH. Aim 1 will determine local CN health in patients with USH by assessing the sensitivity of the electrically evoked compound action potential to changes in interphase gap and pulse polarity. Aim 2 will determine group differences in neural encoding of temporal and spectral cues at the CN between patients with USH and patients with idiopathic hearing loss. Aim 3 will use supervised machine learning techniques to develop an objective tool for assessing the electrode-neuron interface at individual electrode locations. Results of this study have high scientific significance because they will establish how CN degeneration affects neural encoding and processing of electrical stimulation, and identify tests that distinguish the loss of spiral ganglion neurons from the loss of peripheral axons. Results of this study also have high clinical significance because they will 1) lay the groundwork for developing effective, evidence-based clinical practice guidelines for managing patients with USH, and 2) yield an objective tool for assessing the site-specific electrode-neuron interface in all CI users, which is foundational for creating optimal programming maps for individual patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Usher Syndrome, Cochlear Implantation
Keywords
Auditory Electrophysiology

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
44 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Usher Syndrome
Arm Type
Experimental
Arm Description
Adult and pediatric cochlear implant users with Usher syndrome
Arm Title
Idiopathic Hearing Loss
Arm Type
Active Comparator
Arm Description
Adult and pediatric cochlear implant users with idiopathic hearing loss
Intervention Type
Other
Intervention Name(s)
Experimental manipulation of stimulation parameters
Intervention Description
This translational mechanistic study involves changing stimulation parameters (i.e., experimental manipulation) for measuring the electrically evoked compound action potential in order to understand the pathophysiology of the auditory system in patients with Usher syndrome.
Primary Outcome Measure Information:
Title
The electrically evoked compound action potential
Description
The primary outcome measure is the neural response generated by the electrically-stimulated cochlear nerve, which can be considered a health-related, biomedical outcome.
Time Frame
Outcome measures will be obtained from Day 1 through study completion, an average of 2 years.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Minimum of 6 months of listening experience with cochlear implant Diagnosed with Usher syndrome or idiopathic hearing loss Exclusion Criteria: Severe medical comorbidities Electrode malposition or migration as determined based on imaging results
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shuman He, MD, PhD
Organizational Affiliation
Ohio State University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Boston children's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02453
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amanda Griffin, AuD, PhD
Phone
781-216-3657
Email
Amanda.Griffin@childrens.harvard.edu
Facility Name
Gina Hounam
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43205-2664
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gina Hounam
Phone
614-722-5868
Email
Gina.Hounam@nationwidechildrens.org
Facility Name
The Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shuman He, MD, PhD
Phone
614-293-5963
Email
Shuman.He@osumc.edu
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232-8718
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rene Gifford
Phone
615-936-5000
Email
rene.gifford@vanderbilt.edu
First Name & Middle Initial & Last Name & Degree
Rene Gifford, PhD

12. IPD Sharing Statement

Learn more about this trial

Auditory Neural Function in Implanted Patients With Usher Syndrome

We'll reach out to this number within 24 hrs